موافقات الدواء

Amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative
symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.
Amisulpride also regulates secondary negative symptoms in productive state, as well as affective disorders such as depressive mood.